Get the app
USHealthcare

Absci Corp (ABSI)

US · Healthcare · Biotechnology

$9.27+15.30%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$318,000
Revenue YoY
-46.4%
Net profit
$-33.2M
EPS
$-0.21
EPS estimate
$-0.20
Net margin
-10,443.4%

EPS came in at -0.21 against a street estimate of -0.20 — a miss of 5.0%.

Key statistics

Market cap
$1.41B
Forward P/E
0.0
P/B
5.72
Book value
$1.44
EPS (TTM)
$-0.79
52-week high
$12.05
52-week low
$2.24
50-day MA
$9.03
200-day MA
$5.39
Beta
2.44

Analyst view

Analysts rate Absci Corp a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $14.22.

Shareholding

Insiders
11.84%
Institutions
87.18%

Largest institutional holders

FundStake
FMR Inc13.14%
ARK Investment Management LLC8.00%
BlackRock Inc6.56%
State Street Corp4.27%
Redmile Group, LLC3.93%
Vanguard Capital Management, LLC3.43%
Advanced Micro Devices Inc3.33%
Adage Capital Partners Gp LLC3.32%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
ABSCI CORPORATION - QUARTERLY SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $107.9 million in cash and cash equivalents as of June 30, 2026, u
2026-08-11
Results announced · Q3 2026
ABSCI CORPORATION – Q2 2026 FINANCIAL & OPERATING SUMMARY HEADLINE NUMBERS • Cash Position: $201.1 million in cash, cash equivalents, and marketable
2026-08-11
Material agreement · Q2 2026
ABSCI CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Stock offering size: 13,495,277 shares of common stock • Offering price: $7.41 per share • Gross
2026-06-24
Company announcement · Q2 2026
ABSCI CORPORATION (ABSI) - FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201 on June 24
2026-06-24
Shareholder vote results · Q2 2026
ABSCI CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of record date (April 7, 2026): 155,447,428 shares of common stock • A
2026-06-05
Quarterly report · Q1 2026
ABSCI CORPORATION – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash & Liquidity Crisis: Cash and cash equivalents dropped 57% to $8.6 m
2026-05-07
Proxy statement · Q2 2026
ABSCI CORPORATION PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 – Election of Two Class II Directors: Vote to elect Prof Sir
2026-04-22
Annual report FY2025
ABSCI CORPORATION — 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Public company trading on NASDAQ under ticker ABSI; fiscal year ended December 31,
2026-03-24

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Absci Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.